MedPath

Instituto de Medicina Regenerativa

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:1
Completed:1

Trial Phases

1 Phases

Early Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Early Phase 1
3 (100.0%)

Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms

Early Phase 1
Recruiting
Conditions
Neoplasms
First Posted Date
2022-07-26
Last Posted Date
2024-03-06
Lead Sponsor
Instituto de Medicina Regenerativa
Target Recruit Count
100
Registration Number
NCT05475106
Locations
🇲🇽

Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico

Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms

Early Phase 1
Completed
Conditions
Neoplasms
First Posted Date
2020-08-11
Last Posted Date
2024-03-06
Lead Sponsor
Instituto de Medicina Regenerativa
Target Recruit Count
30
Registration Number
NCT04509167
Locations
🇲🇽

Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

Early Phase 1
Active, not recruiting
Conditions
ARDS, Human
Covid-19
First Posted Date
2020-07-02
Last Posted Date
2024-03-06
Lead Sponsor
Instituto de Medicina Regenerativa
Target Recruit Count
9
Registration Number
NCT04456361
Locations
🇲🇽

Instituto de Medicina Regenerativa, Tijuana, Baja California, Mexico

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.